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A B S T R A C T
Spinal cord pathology is a feature of both neuromyelitis optica spectrum disorder (NMOSD) and relapsing-
remitting multiple sclerosis (MS). While subclinical disease activity has been described in MS using quantitative
magnetic resonance imaging measures, current evidence suggests that neurodegeneration is absent between
relapses in NMOSD, although most evidence comes from brain studies. We aimed to assess cross-sectional dif-
ferences and longitudinal changes in myelin integrity in relapse-free MS and NMOSD subjects over one year. 15
NMOSD, 15 MS subjects, and 17 healthy controls were scanned at 3 T using a cervical cord mcDESPOT protocol.
A subset of 8 NMOSD, 11 MS subjects and 14 controls completed follow-up. Measures of the myelin water
fraction (fM) within lesioned and non-lesioned cord segments were collected. At baseline, fM in lesioned and non-
lesioned segments was signiﬁcantly reduced in MS (lesioned: p = 0.002; non-lesioned: p = 0.03) and NMOSD
(lesioned: p = 0.0007; non-lesioned: p = 0.002) compared to controls. Longitudinally, fM decreased within non-
lesioned cord segments in the MS group (−7.3%, p = 0.02), but not in NMOSD (+5.8%, p = 0.1), while
change in lesioned segments fM did not diﬀer from controls' in either patient group. These results suggest that
degenerative changes outside of lesioned areas can be observed over a short time frame in MS, but not NMOSD,
and support the use of longitudinal myelin water imaging for the assessment of pathological changes in the
cervical cord in demyelinating diseases.
1. Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing
autoimmune disease of the central nervous system that, due to similar
clinical and neurological features, was long thought to be a rare variant
of multiple sclerosis (MS) (Wingerchuk et al., 2015). Since the dis-
covery of a highly speciﬁc antibody (Jarius and Wildemann, 2010), and
the advent of serum testing to aid diﬀerential diagnosis, it is now
considered a separate entity (Weinshenker, 2007). Serum antibodies to
the aquaporin-4 water channel protein (AQP4-Ab), found on astrocytic
foot processes, are detectable in a high proportion of patients (Pandit
et al., 2015). AQP4 is expressed throughout the brain, and is found in
particularly high concentration in the optic nerve and spinal cord, in
line with the observed frequency of pathology in these regions in
NMOSD (Pittock et al., 2006).
Unlike in MS, which can present as a relapsing-remitting disease
with secondary conversion to a progressive phase, or as progressive
from onset (Compston and Coles, 2008), conversion to a progressive
phase is extremely rare in NMOSD (Aboul-Enein et al., 2013; Cabre
et al., 2009; Collongues et al., 2010, 2014). Clinical disability is accrued
as a consequence of damage sustained during relapses, whereas clinical
disability scores in MS increase more steadily during the progressive
phase (Collongues et al., 2011; Wingerchuk et al., 2007a). Current
clinical and neuroimaging evidence suggests that subclinical disease
activity does not occur between attacks in NMOSD (Wingerchuk et al.,
2007b), contrary to what is observed in MS (Filippi and Agosta, 2010;
Matthews et al., 2015). However, it has been suggested that NMOSD
attacks are so severe that the resulting sequelae hide the subtler
changes that may accrue over time as a result of progressive axonal
deterioration following inﬂammation (Wingerchuk et al., 1999).
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The cervical spinal cord is a frequent target of disease activity in
both NMOSD and MS. The main feature of cord pathology in NMOSD is
the presence of longitudinally extensive lesions, spanning three or more
vertebral segments. These favour the grey matter (Krampla et al., 2009;
Nakamura et al., 2008) and are characterised by abnormal magnetic
resonance imaging (MRI) diﬀusion metrics, reﬂecting greater tissue
injury compared with MS lesions (Klawiter et al., 2012; Rivero et al.,
2014). Abnormal magnetization transfer (Benedetti et al., 2006; Filippi
et al., 1999; Rocca et al., 2004) and diﬀusion parameters (Jeantroux
et al., 2012; Pessôa et al., 2012; Qian et al., 2011; Rivero et al., 2014)
have been observed in the cervical cord in NMOSD, suggesting the
presence of inﬂammatory processes, demyelination and axonal pa-
thology. Abnormally low myo-inositol (normalized to creatine) levels
have been measured in the upper cervical cord, thought to reﬂect as-
trocytic dysfunction within lesions, a process thought to play a major
role in the pathogenesis of the disease by contributing to oligoden-
drocyte dysfunction and eventually secondary demyelination (Ciccarelli
et al., 2013).
Overall, focal cord pathology is considered more aggressive in
NMOSD; diﬀuse damage of the type seen in MS has only been shown
inconsistently, while secondary degenerative processes in white matter
tracts may be common to both diseases (Klawiter et al., 2012). How-
ever, the majority of studies do not diﬀerentiate between lesional and
normal-appearing spinal cord tissue (NASCT); to date, no longitudinal
advanced imaging study has assessed whether changes in NASCT occur
in NMOSD outside of clinical relapses.
Multicomponent Driven Equilibrium Single Pulse Observation of T1
and T2 (mcDESPOT) is a quantitative myelin water imaging method
with great sensitivity for the estimation of myelin content (Deoni et al.,
2008), and has been suggested as a possible marker of disease pro-
gression in primary progressive MS (Kolind et al., 2015). Matthews
et al. (2015) previously found no evidence of disease progression in a
group of clinically stable NMOSD subjects, while several quantitative
imaging brain metrics, including the mcDESPOT-derived myelin water
fraction (fM) in major white matter tracts, showed widespread diﬀer-
ences and changes over one year in a group of relapsing-remitting MS
subjects. In the present study, we report cross-sectional and long-
itudinal evaluations of the cervical spinal cord in a subset of the same
NMOSD, MS subjects and healthy controls using mcDESPOT. We aimed
to characterise normal-appearing and lesional cervical cord pathology
at baseline, and to assess whether evidence of degenerative changes
could be detected over one year in either patient group.
2. Methods
2.1. Population characteristics and study design
2.1.1. Ethics
This study was approved by the South East Hampshire NHS
Research Ethics Committee. All participants gave written informed
consent before taking part.
2.1.2. Subjects
15 AQP4-Ab NMOSD patients, 15 relapsing-remitting MS patients,
and 17 sex and age-matched healthy controls were recruited from the
NHS Neuromyelitis Optica Highly Specialized Service in Oxford, UK – a
subset of the groups previously reported on in Matthews et al. (2015).
All NMOSD subjects were receiving immunosuppressant medication (7
on azathioprine, 2 on methotrexate, 1 on prednisone, and 5 on com-
binations thereof), while the majority of MS subjects were on disease-
modifying therapies (6 on Copaxone, 3 on beta-interferons, and 1 on
low-dose naltrexone; 5 were not receiving treatment). A subset of 8
NMOSD, 11 MS and 14 controls completed a follow-up scan after one
year. All patients had been relapse-free for at least 6 months prior to the
baseline scan, and none experienced a relapse between baseline and
follow-up.
2.1.3. MRI acquisition
Participants were scanned on a 3 Tesla MRI scanner (Siemens
MAGNETOM Verio, Erlangen, Germany) with a mcDESPOT protocol
(Kolind and Deoni, 2011) which covered the whole cervical cord with
0.9 × 0.9 × 1.8 mm voxels, reconstructed to 0.9 mm3 isotropic (scan
time 22 min). The mcDESPOT data consisted of series of spoiled gra-
dient echo (SPGR) scans over a range of 8 optimized ﬂip angles (α) (TE/
TR = 2.7/6.1 milliseconds (ms); α= [2.25, 4.5, 6.75, 9, 11.25, 13.5,
15.75, 18]°), 8 balanced steady state free precession scans (TE/
TR = 2.3/4.6 ms; α= [5.625, 11.25, 16.875, 22.5, 28.125, 33.75,
39.375, 45]°) acquired over two phase-cycling patterns (0° and 180°) to
correct for oﬀ-resonance eﬀects (Deoni, 2009), and an inversion re-
covery-prepared SPGR scan for correction of B1 inhomogeneity (Deoni,
2011) (TE/TR = 2.7/6.3 ms, TI = 450 ms, α= 5°). An axial T2-
weighted multi-echo gradient echo sequence, sagittal T1-weighted
magnetization-prepared rapid gradient echo, and a sagittal T2-weighted
turbo spin echo sequence were acquired for lesion assessment.
2.2. Image analysis
2.2.1. Lesion identiﬁcation
Lesions were identiﬁed on the patients' anatomical scans by an ex-
perienced radiologist (J.S.L.) blinded to diagnosis, primarily based on
the sagittal T2-weighted scan with additional information gleaned from
the sagittal T1 and axial T2-weighted scans. The assessment was done
for both baseline and follow-up concurrently. Spinal levels (heretofore
referred to as segments) were identiﬁed as normal-appearing or le-
sioned. For small lesions located at a disc level, both adjoining segments
were considered lesioned.
2.2.2. Segmentation
For each subject, an SPGR image from the mcDESPOT protocol with
good contrast between tissue and cerebrospinal ﬂuid (α= 9°) was used
for preprocessing. The spinal cord was segmented using PropSeg (De
Leener et al., 2014), a semi-automated propagation-based method from
the Spinal Cord Toolbox (De Leener et al., 2016) (SCT; http://
sourceforge.net/projects/spinalcordtoolbox/). Each subject's SPGR
was warped to the MNI-Poly-AMU template (Fonov et al., 2014). The
inverse transform was then applied to the template in order to obtain
vertebral level segmentation in subject space. We considered the region
from C1 to C7 for whole cervical cord measures. Using the lesion as-
sessment described above, separate masks were created by considering
only segments marked as either normal-appearing or lesioned. An ex-
ample of a lesioned tissue mask is shown in Fig. 1.
2.2.3. fM measurement
Images from the mcDESPOT protocol were linearly registered
within-subject to the reference SPGR scan with FSL-FLIRT (Jenkinson
et al., 2002), using trilinear interpolation. fM maps were calculated with
a three-pool model (Deoni et al., 2013), and manually edited (by an
observer blinded to group and time point (A.J.E.C.)) to exclude voxels
where partial volume eﬀect in the acquired images led to artiﬁcially
very low computed values. Visual inspection was performed for all
images to ensure the quality of co-registration. Median fM values were
collected within the whole cervical cord, and within NASCT and le-
sioned tissue separately using the masks described above.
2.3. Statistics
Non-parametric tests were chosen due to small sample sizes, and
after visual inspection showed that MRI variables were not normally
distributed. Percent changes between baseline and follow-up metrics
were calculated for each subject. Diﬀerences between patient groups
were evaluated using the Mann-Whitney U test, and between the three
groups using the Kruskal-Wallis test. Post hoc comparisons following a
signiﬁcant omnibus test (alpha = 0.05) were conducted with the Mann-
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Whitney U test. Within-group diﬀerences were assessed using paired
Wilcoxon's signed rank test; we tested cross-sectional diﬀerences be-
tween NASCT and lesional segments within each patient group, and
changes over time within each group and tissue type. Results were not
corrected for multiple comparisons, due to the exploratory nature of
this study. Statistical analysis was conducted in R version 3.3.3 (R Core
Team, 2017).
3. Results
Subject characteristics are summarized in Table 1. There was no
signiﬁcant diﬀerence in age between the three groups (p = 0.6). Both
patient groups had equivalent disease duration (p = 0.6). The NMOSD
group had a higher median EDSS (p = 0.03). Summary baseline and
longitudinal MRI metrics, and group comparisons are displayed in
Table 2.
3.1. Cross-sectional
3.1.1. Lesion identiﬁcation
Four MS subjects had lesions spanning the whole cervical cord, and
one had no detectable lesions. Two NMOSD subjects had lesions
spanning the whole cord, and three had none. The number of lesional
segments per subject did not diﬀer signiﬁcantly between groups
(p = 0.1) (see Supplementary materials).
3.1.2. fM in NASCT and lesioned tissue (Fig. 2)
fM was signiﬁcantly reduced in the NASCT for both MS (on
average− 9.66%, p = 0.03) and NMOSD (−9.8%, p = 0.002) com-
pared to controls. fM in lesioned areas was also reduced in both MS
(−14.9%, p = 0.002) and NMOSD (−16.4%, p = 0.0007). Neither
NASCT nor lesioned tissue fM diﬀered between MS and NMOSD. There
were no signiﬁcant diﬀerences between NASCT and lesional areas
within either patient group. Example maps are shown in Fig. 3.
3.2. Longitudinal
Additional information regarding baseline metrics for the long-
itudinal subset can be found in Supplementary materials. The results
observed at baseline overall held true for the subset of subjects who
took part in the longitudinal part of the study. In the MS group, three
subjects had an increase of 0.5 points on the EDSS, and two subjects a
decrease of 0.5 points; all of them had a baseline EDSS≤ 4.5. In the
NMOSD group, one subject had an increase of 0.5 points from 5.5 to 6,
and one had a one-point decrease from 7.5 to 6.5.
3.2.1. Lesion identiﬁcation
None of the subjects developed any new cervical cord lesions be-
tween baseline and follow-up. Within the longitudinal MS sample
(n = 11), one subject had no lesions, therefore lesional analysis in-
cluded 10 patients; 3 had entirely lesioned cords, therefore NASCT
analysis only included 8 patients. Within the NMOSD group, all 8
subjects had some degree of NASCT tissue, and one had no lesions,
therefore 7 patients were included in lesional analysis.
3.2.2. Changes in fM in NASCT and lesioned tissue (Fig. 4)
Median percent change in fM was −0.9% in controls. In NASCT,
there was a greater reduction in the MS group (−7.3%) compared to
controls (−0.9%, p = 0.02) and NMOSD (+5.8%, p = 0.002). There
was no diﬀerence between controls and NMOSD. Within lesioned tissue,
the MS group showed a median decrease of −1.42%, and the NMOSD
group increased by +3.05%. A Kruskal-Wallis test revealed that there
was no signiﬁcant diﬀerence between change in NASCT in controls and
change in lesioned tissue for both patient groups. Testing for sig-
niﬁcance of change within-group, only the decrease in NASCT in the MS
group was signiﬁcant (p = 0.02).
4. Discussion
Using myelin water imaging, we found that measures of myelin
content are similarly reduced in MS and NMOSD compared to controls
in cervical spinal cord lesions and in normal-appearing cervical spine
tissue. At one-year follow-up, we observed a reduction in myelin con-
tent in NASCT in MS, but not in NMOSD, without intervening relapses.
There was no signiﬁcant change in myelin content in lesioned segments
over time in either group. There were no within-group diﬀerences be-
tween NASCT and lesional areas for either MS or NMOSD.
Our ﬁndings complement those of a recent investigation by
Matthews et al., which included the subjects enrolled in the present
study (Matthews et al., 2015). Their results showed evidence of wide-
spread non-lesional brain injury in the MS group only, using several
MRI parameters including volumetric measures, myelin water imaging
and diﬀusion tensor imaging. No changes in brain metrics were found
after one year in NMOSD, while evidence of ongoing neurodegenera-
tion was seen in the relapsing-remitting MS group.
The presence of diﬀuse abnormalities in the MS cervical cord is
well-documented (Gass et al., 2015), although these may also be at-
tributed to lesions not visible on conventional MRI (e.g. below the
Fig. 1. Example of a T2-hyperintense lesion (arrows) in an NMOSD patient at the C1/C2
level (left), and cord segmentation on an SPGR image from the mcDESPOT protocol
(right). The area at the C1/C2 level was categorized as lesioned (in red), and the re-
maining portion of the cord as preserved tissue (in green). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
Table 1
Population characteristics for the cross-sectional sample (median (range)). Group com-
parisons are performed with the Kruskal-Wallis test. Where only pairwise MS vs. NMOSD
comparisons are appropriate, results from the Mann-Whitney U test are reported.
Controls MS NMOSD p
N (Sex) 17 (4 M) 15 (4 M) 15 (3 M) –
Age (years) 54 (19–76) 41 (22–68) 45 (20–76) 0.6
Disease duration (months) – 72 (24–254) 60 (12–186) 0.6
Baseline EDSS – 2 (0–5) 4 (2–7.5) 0.03⁎
Lesioned segments per subject – 5 (0–7) 3 (0–7) 0.1
Number of subjects with
NASCT
– 11 13 –
Number of subjects with ≥1
lesion
– 14 12 –
Number of subjects with no
lesions
– 1 3 –
NASCT: normal-appearing spinal cord tissue.
⁎ Signiﬁcant at p≤ 0.05.
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imaging resolution), or distal eﬀects of damage to regions outside the
cervical cord. Given comparable degrees of demyelination in the cord at
baseline, the diﬀerences observed between MS and NMOSD groups over
time may reﬂect distinct inﬂammatory and neurodegenerative pro-
cesses (Kawachi and Lassmann, 2017), and may be consistent with the
hypothesis of a primary neurodegenerative process in MS (Stys et al.,
2012) that would be absent in NMOSD. Further evaluation of the eﬀects
of the location and extent of focal cord pathology are however required
before claims can be made regarding the pathological substrates of
these observations.
While the existence of diﬀuse damage in the brain in NMOSD is
disputed, widespread abnormalities in the cervical spinal cord have
been observed before (Jeantroux et al., 2012; Klawiter et al., 2012;
Qian et al., 2011). Abnormal mean and perpendicular diﬀusivity
parameters have been attributed to inﬂammation and demyelination,
respectively, rather than axonal loss (Qian et al., 2011). Our ﬁndings
bring further evidence for the presence of demyelination outside of
lesional areas. Further, Klawiter et al. found abnormal diﬀusion para-
meters in tracts up- and downstream of lesioned areas, but not in those
tracts that were unrelated to lesions (Klawiter et al., 2012). Secondary
degeneration of white matter tracts following focal damage may
therefore explain loss of myelin in adjacent areas. Since subjects in the
present study were relapse-free for a minimum of 6 months before en-
rolment, it is likely that any lesion-related secondary changes would
have already occurred at the time of baseline scan, hence the lack of
chronic progression over the subsequent year. Alternatively, the ab-
normalities observed in NASCT may be the consequence of previous
focal damage, resolved at the time of scanning but leaving residual
abnormalities in the white matter not seen on conventional imaging,
but to which myelin water imaging is sensitive. Our results of stable fM
in NASCT over one year suggest that, once these changes have occurred,
normal-appearing areas are not subject to further chronic degeneration,
which supports the observation that disease progression is absent
clinically in NMOSD.
An important limitation of the current approach lies in the seg-
mentation of lesioned areas, which include varying proportions of
NASCT, and are therefore lesioned areas and not purely lesioned tissue
per se. While this approach enables isolation of NASCT, it does not
constitute lesion segmentation per se, and thus limits the speciﬁcity of
this measure to lesional pathology. This may contribute to explain the
lack of signiﬁcant baseline diﬀerences between NASCT and lesioned
areas in each patient group, as would be expected, although the ob-
served extent of damage to NASCT areas is another contributing factor.
We did not diﬀerentiate between upstream and downstream lesional
Table 2
Median (interquartile range) baseline values and percent change in MRI metrics.
Controls MS NMOSD Kruskal-Wallis MS vs. controls NMOSD vs. controls NMOSD vs. MS
Cross-sectional
NASCT fM 0.159 (0.017) 0.148 (0.016) 0.149 (0.015) 0.006⁎⁎ 0.03⁎ 0.002⁎⁎ 0.8
Lesioned tissue fM – 0.140 (0.023) 0.138 (0.035) 0.0009⁎⁎⁎ 0.002⁎⁎ 0.0007⁎⁎⁎ 0.7
NASCT vs. lesioned tissuea – 0.9 0.3 – – – –
Longitudinal
Change in NASCT fM −0.9% (7.0);
p = 0.7
−7.3% (5.2);
p = 0.02⁎
+5.8% (10.2);
p = 0.1
p = 0.004⁎⁎ p = 0.02⁎ p = 0.1 p = 0.002⁎⁎
Change in lesioned tissue fM – −1.4% (7.6);
p = 0.4
+3.1% (10.5);
p = 0.2
p = 0.2 – – –
fM: myelin water fraction. NASCT: normal-appearing spinal cord tissue.
⁎ p≤ 0.05.
⁎⁎ p≤ 0.01.
⁎⁎⁎ p≤ 0.001.
a Within-group paired Wilcoxon signed-rank test.
Fig. 2. Median myelin water fraction (fM) for the cross-sectional sample, by group and
tissue type: normal-appearing spinal cord tissue (NASCT) and lesioned segments. Right-
hand axis shows percent diﬀerence of each data point from the control group average.
Data points outside of boxplot whiskers are outliers, deﬁned as being beyond 1.5 inter-
quartile range of each quartile. *Signiﬁcant at p≤ 0.05, **p≤ 0.01, ***p≤ 0.001.
Fig. 3. Example myelin water fraction (fM) maps overlaid on an SPGR scan. (a) Healthy
control: female, 26 years old. (b) MS subject: male, 35 years old, EDSS 2, disease duration
of 4 years, with lesions at the C1 and C2 levels. (c) NMOSD subject: female, 41 years old,
EDSS 3.5, disease duration of 2 years, with a lesion at the C2/C3 level. White lines re-
present upper and lower limits for cord segments identiﬁed as lesioned. Reduced fM is
visible in lesions and along the length of the cord for both patients.
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inﬂuences on normal-appearing tissue, and results obtained in lesional
areas are likely to reﬂect heterogeneity in the size, type, and age of
lesions. Moreover, there is heterogeneity of normal myelin concentra-
tions at diﬀerent levels of the cervical cord due to variations in white to
grey matter ratio (Fradet et al., 2014; Kolind and Deoni, 2011). How-
ever, the distribution of lesions across cord levels was uniform within
and between each disease group, thus mitigating possible bias in
comparing unmatched regions that are expected to vary in myelin
content.
Half of the MS and all of the NMOSD subjects were on im-
munomodulatory and immunosuppressant treatments, respectively.
While all included patients were in remission for the course of the
study, disease-modifying therapies are likely to mediate background
inﬂammatory activity, and thus may aﬀect changes in myelin content
over one year compared to patients not currently on treatment, al-
though discussions on the eﬀects of DMTs on spinal cord pathology in
the current context remain speculative. Characterisation of the inﬂu-
ence of volume changes (i.e. atrophy) on the fM measurements would
also be of interest to allow description of the relationship between
possible volume loss and changes in myelin content.
Limitations to this study also include the very small sample size,
especially for the longitudinal sample, and resulting heterogeneity in
age and clinical proﬁles within the patient groups. Therefore, results
should be regarded as preliminary and warrant replication in larger
samples. However, detection of signiﬁcant changes over a short period
in a small population strongly supports the potential use of cervical
cord myelin water imaging as a marker of ongoing demyelination in
MS.
5. Conclusion
Using a myelin water imaging protocol, we detected cross-sectional
diﬀerences in normal-appearing tissue in NMOSD and relapsing-re-
mitting subjects compared to healthy controls. There was a signiﬁcant
decrease in fM over one year in the MS NASCT, suggesting that chronic
ongoing demyelination in non-lesional areas may occur in relapsing-
remitting subjects. These results also attest to the ability of mcDESPOT
to show evidence of degenerative processes in the relapsing-remitting
MS cord over a relatively short follow-up duration. Further longitudinal
investigations should address the link between such changes and pro-
gression of disability in order to establish its potential use as a clinically
relevant marker of pathology. In contrast, despite severe diﬀuse da-
mage at baseline, no signiﬁcant change in myelin content was seen in
NMOSD in normal-appearing areas over time. This observation lends
new evidence to the theory that subclinical disease activity is absent in
NMOSD.
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